Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BUTEO trial of BTT1023 in primary sclerosing cholangitis
ISRCTN11233255Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of timolumab in Primary Sclerosing Cholangitis (PSC), sponsored by University of Birmingham. Primary endpoint: Biochemical response in alkaline phosphatase. Started Apr 2015; status: completed.
02
Drugs
timolumab
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on ISRCTN11233255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11233255.